The frequency of CYP2C19 PMs (the genotypes *2/*2 and *2/*3 but not *3/*3 were found in this study) was significantly higher among the ESCC patients than in the control group (20.70% vs 13.86%). This evidence concerns the gene CYP2C19 and esophageal squamous cell carcinoma.